Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes

Hepatology

Volumn 52, Issue 1, 2010, Pages 33-37

  Montes Cano, Marco Antonio ^a   García Lozano, José Raúl ^a   Abad Molina, Cristina ^a   Romero Gómez, Manuel ^b   Barroso, Natalia ^a   Aguilar Reina, José ^a   Núñez Roldán, Antonio ^a   González Escribano, María Francisca ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 28; RIBAVIRIN;

ALLELE; ARTICLE; ASSAY; COHORT ANALYSIS; DISEASE ASSOCIATION; ETHNICITY; FEMALE; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERSISTENT INFECTION; PRIORITY JOURNAL; RISK; TREATMENT RESPONSE; VIRUS INFECTION; VIRUS TYPING;

COHORT STUDIES; FEMALE; GENETIC LOCI; GENETIC VARIATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKINS; MALE; SPAIN;

EID: 77954225315     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23624     Document Type: Article

References (16)

1. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005;9:383-398.
2. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immunoglobulin: Irish Hepatology Research Group. N Engl J Med 1999;340:1228-1233.
3. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008;49: 634-651.
4. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;46:399-401.
5. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-a and ribavirin therapy. Nat Genet 2009;41:1100-1104.
6. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-a and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-1109.
7. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801.
8. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-373.
9. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-1097.
10. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, el al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. HEPATOLOGY 2003;37:600-609.
11. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-527. (Pubitemid 41096640)
12. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-134.
13. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009;24:336-345.
14. Pang PS, Planet PJ, Glenn JS. The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. PLoS One 2009;11:e6579.
15. Telenti A. Adaptation, co-evolution, and human susceptibility to HIV-1 infection. Infect Genet Evol 2005;5:327-334.
16. Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, Addo M, et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009;458:641-645.